Welcome to LookChem.com Sign In|Join Free
  • or


Post Buying Request

220127-57-1 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Imatinib mesylate
Cas No: 220127-57-1
USD $ 1.0-1.0 / Kilogram 1 Kilogram 100 Kilogram/Month HANWAYS CHEMPHARM CO.,LIMITED Contact Supplier
High Purity Imatinib Mesylate In Stock
Cas No: 220127-57-1
No Data 1 Kilogram 200 Kilogram/Month Hangzhou Sartort Biopharma Co., Ltd Contact Supplier
Imatinib mesylate
Cas No: 220127-57-1
No Data 1 Metric Ton 1 Metric Ton/Week Anhui Haikang Pharmaceutical Co., Ltd. Contact Supplier
Imatinib mesylate
Cas No: 220127-57-1
No Data No Data No Data Shanghai Yanchu chemicals Co., Ltd Contact Supplier
Imatinib mesylate Manufacturer/High quality/Best price/In stock
Cas No: 220127-57-1
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Dayang Chem (Hangzhou) Co.,Ltd. Contact Supplier
Imatinib Mesylate Chinese leading supplier
Cas No: 220127-57-1
No Data 1 Kilogram Metric Ton/Day Sinoway Industrial Co., Ltd. Contact Supplier
Imatinib mesylate 220127-57-1
Cas No: 220127-57-1
No Data 1 Gram 10 Kilogram/Day Hubei Vanz Pharm Co.,Ltd Contact Supplier
High purity Various Specifications Imatinib Mesylate CAS:220127-57-1
Cas No: 220127-57-1
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
High quality Imatinib Mesylate supplier in China
Cas No: 220127-57-1
No Data No Data Metric Ton/Day Simagchem Corporation Contact Supplier
Imatinib Mesylate
Cas No: 220127-57-1
No Data 25 Kilogram 10 Metric Ton/Year Hefei TNJ chemical industry co.,ltd Contact Supplier

220127-57-1 Usage

a small-molecule inhibitor

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.


In May 2001, the FDA approved imatinib as a new cancer drug after a record review time of just 2.5 months. Imatinib was launched as Gleevec in the US for chronic myelogenous leukemia (CML) in blast crisis, accelerated phase or chronic phase after interferon-alpha failure. This compound can be prepared by a four step sequence from a condensation of the 1-(3-pyridyl)ethanone with dimethyl formamide dimethylacetal, followed by successive cyclization with the methyl-nitrophenyl guanidine, hydrogenolysis and condensation with the benzoyl chloride of the methylpiperazine. Imatinib is the first of a new class of anticancer drugs that are specifically designed to target the molecular pathways involved (oncogenic event) in the development of disease. The Brc-Abl oncoprotein is a constitutively active tyrosine kinase that causes CML. Imatinib is a competitive inhibitor of this tyrosine kinase as well as Abl, Kit and the PDGFR kinases It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates and consequently blocks the proliferation of the leukemic cells. Phase II studies demonstrated that in chronic phase CML, over 90% of the patients had their leukocyte counts return to normal and 56% had a major cytogenic response. No phase III data is currently available. It is clear from the evidence available that imatinib has advantages over IFN-alpha, such as reduced toxicity, more rapid hematological response, higher rate of cytogenic response and oral administration. The drug is well tolerated, producing few side effects, classified as grade 1 nausea, muscle cramps, diarrhea, edema and vomiting. Imatinib is metabolized primarily by the CYP3A4 enzyme system and drugs capable of modulating this system would be expected to modify the patient's exposure. Novartis expects to launch imatinib for the treatment of gastrointestinal stromal tumors in 2002.

Chemical Properties

Off-White Solid


Novartis (Switzerland)


A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)


Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib


Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.


echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis


ChEBI: A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.

Brand name

Gleevec, Glivec

General Description

Imatinib is available in 100- and 400-mg capsules for oraladministration and is indicated for the treatment of CML,gastrointestinal stromal tumors (GIST) that express Kit andacute lymphoplastic leukemia that is positive for thePhiladelphia chromosome.Bioavailability of the agent is nearly 100% by the oralroute. The agent is highly protein bound and metabolized tothe N-desmethyl derivative by CYP3A4-mediated removalof the piperazinyl methyl group. The resulting metabolite issimilar to the parent in activity. Elimination occurs primarilyin the feces, and the terminal half-life is 18 hours forthe parent and 40 hours of the N-desmethyl metabolite.Resistant forms of the TK are known, which have alteredamino acids that prevent binding. In addition, there may beincreased levels of the kinase itself. The drug is also a substratefor Pgp and an additional efflux transporter known asbreast cancer resistance protein (BCRP), both of which removethe drug from the cell. These transporters are also inhibitedby the agent as well. Severe side effects include ascites,neutropenia, thrombocytopenia, skin rash, andpulmonary edema. Less serious side effects include nausea/vomiting, heartburn, and headache but overall, the agentis better tolerated than most other medications used in treatingthe disease.

Biochem/physiol Actions

Imatinib mesylate is a tyrosine kinase inhibitor with antineoplastic activity. Imatinib is a potent inhibitor of the Bcr-Abl kinase encoded by the bcr-abl oncogene as well as receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Imatinib mesylate inhibition of Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality found in CML decreases proliferation and enhances apoptosis in leukemias CML and ALL. Inhibition of c-kit tyrosine activity inhibits mast-cell and cellular proliferation in those diseases overexpressing c-kit such as gastrointestinal stromal tumor (GIST).


1) Buchdunger, et al.(1996) Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylpyrimidine Derivative; Cancer Res. 56 100 2) Heinrich et al (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 925 3) Morioka et al. (2016) Effect of Collagen Type 1 or Human Fibronectin on Imatinib Cytotoxicity in Oral Squamous Cell Carcinoma; Pharmacology and Pharmacy, 7 255 [Focus Biomolecules Citation] 4) Hazekawa et al. (2017) Assessment of cytotoxicity of imatinib for oral squamous cell carcinoma by a real-time cell analysis system; E. J. Bio., 13 56 [ Focus Biomolecules Citation]

220127-57-1 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
TCI America (I0936)  Imatinib Mesylate  >98.0%(HPLC) 220127-57-1 100mg 490.00CNY Detail
TCI America (I0936)  Imatinib Mesylate  >98.0%(HPLC) 220127-57-1 1g 2,450.00CNY Detail
Sigma-Aldrich (Y0001692)  Imatinib for system suitability  EuropePharmacopoeia (EP) Reference Standard 220127-57-1 Y0001692 1,880.19CNY Detail
Sigma-Aldrich (Y0001691)  Imatinib mesilate  EuropePharmacopoeia (EP) Reference Standard 220127-57-1 Y0001691 1,880.19CNY Detail
Sigma (SML1027)  Imatinib mesylate  ≥98% (HPLC) 220127-57-1 SML1027-10MG 361.53CNY Detail
Sigma (SML1027)  Imatinib mesylate  ≥98% (HPLC) 220127-57-1 SML1027-100MG 1,232.01CNY Detail



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017


1.1 GHS Product identifier

Product name imatinib methanesulfonate

1.2 Other means of identification

Product number -
Other names Imatinib mesylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:220127-57-1 SDS

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 220127-57-1